TICKERNERD
Menu
ALHCALHCHealthcare · Healthcare Plans

ALHC Stock Forecast: Alignment Healthcare, Inc. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$8.14
+10.08% on the day

The 15 Wall Street analysts covering Alignment Healthcare, Inc. hold a median 12-month price target of $10 — +22.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 42 of 100 as at 4 Nov 2026 — in the lower half.

Market cap
$1.5B
Ticker Nerd rank
42/ 100
Median analyst target
$10
Analysts covering
15
Revenue$1.3B+31.6% y/y
Operating income$42.1M
Net income$36.6M
Free cash flow−$27.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.6%
1M
+2.5%
YTD
−58.8%
1Y
−52.4%
From 52W high
−66.9%
From 52W low
+16.2%
$7
$25
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ALHC stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alignment Healthcare, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
42/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
77
Growth
67
Value
64
Quality
55
Accruals
52
Revisions
43
Issuance
41
Size
38
Momentum
18

Volatility (77): The share price has been relatively steady.

Momentum (18): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ALHC stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALHC, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25Jan 26Apr 26Jul 26Oct 26ALHCHigh $17Median $10Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says15 analysts
9 Buy6 Hold0 Sell
Low $8Median $10High $17

The green dot is the last close — the median target sits +22.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 10 moved it down.

DateFirmActionRatingTarget
2 Nov 2026TD CowenMaintainsBuy$12 → $10
31 Oct 2026UBSMaintainsNeutral—
30 Oct 2026BarclaysMaintainsEqual-Weight$10 → $9.00
30 Oct 2026JP MorganMaintainsOverweight$10 → $8.00
30 Oct 2026KeybancDowngradeSector Weight—
30 Oct 2026UBSMaintainsNeutral$9.00 → $8.00
28 Oct 2026NeedhamInitiatesHold—
12 Oct 2026TD CowenMaintainsBuy$21 → $12
12 Oct 2026TD CowenMaintainsBuy—
12 Oct 2026UBSMaintainsNeutral$22 → $9.00
12 Oct 2026UBSMaintainsNeutral—
9 Oct 2026JP MorganMaintainsOverweight$22 → $10
9 Oct 2026JP MorganMaintainsOverweight—
9 Oct 2026KeybancMaintainsOverweight—
9 Oct 2026KeybancMaintainsOverweight$28 → $12
9 Oct 2026William BlairDowngradeMarket Perform—
9 Oct 2026William BlairDowngradeMarket Perform—
6 Oct 2026BarclaysMaintainsEqual-Weight$16 → $10
6 Oct 2026BarclaysMaintainsEqual-Weight—
4 Aug 2026JP MorganMaintainsOverweight$26 → $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

ALHC appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ALHC vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Alignment Healthcare, Inc. returned −52.4% against +14.8% for the S&P 500, dividends included.

ALHC vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120140Jan 26Apr 26Jul 26Oct 26ALHCS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ALHC analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
EPS revision, 90 days
−45.5%
Analysts raising
0
Analysts cutting
0
Fundamentals

Alignment Healthcare, Inc. (ALHC) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
52.8×

Cheaper than 13% of US stocks

Price / sales
0.3×

Cheaper than 87% of US stocks

Price / book
5.6×

Cheaper than 17% of US stocks

EV / EBITDA
15.1×

Cheaper than 23% of US stocks

Growth & margins
Revenue growth (YoY)
36.7%

Higher than 81% of US stocks

Earnings growth (YoY)
31.6%

Higher than 67% of US stocks

Gross margin
13.5%

Higher than 13% of US stocks

Operating margin
−0.3%

Higher than 31% of US stocks

Net margin
0.6%

Higher than 48% of US stocks

Returns & dividend
Return on equity
13.2%

Higher than 71% of US stocks

Return on assets
2.3%

Higher than 60% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Alignment Healthcare, Inc. (ALHC) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Alignment Healthcare, Inc. has a market value of $1.5B and an enterprise value of $1.1B.

  • Revenue in the twelve months to 30 June 2026: $4.6B. The latest quarter grew 36.7% year on year.

  • Net income over the same four quarters: $40.7M, a 0.9% net margin.

  • Diluted earnings per share, trailing twelve months: $0.19.

  • Free cash flow in the twelve months to 30 June 2026: $177.5M.

  • Shares outstanding: 207.2M.

  • Trailing P/E: 52.8×; forward P/E: 13.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Alignment Healthcare, Inc. employs 1,849 people — $2.5M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 4 Nov 2026

Data provided by Twelve Data

Peers

ALHC vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealthcare Plans
CompanyMarket capTKN rank
ALHCAlignment Healthcare, Inc.$1.5B42
PGNYProgyny, Inc.$2.4B99
CLOVClover Health Investments Corp.$2.4B72
OSCROscar Health, Inc.$10.5B90
MOHMolina Healthcare, Inc.$11.8B34
CNMDCONMED Corp.*$1.7B92
NUVBNuvation Bio, Inc.*$1.7B67

* Nearest Healthcare names by size — few healthcare plans companies of this scale trade in the US universe.

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alignment Healthcare, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALHC news & analysis

ALHC Investigation Reminder: Alignment Healthcare Inflated EBITDA Triggers Securities Fraud Investigation for Investors – Contact BFA Law if You Lost Money

GlobeNewsWire · 4 Nov 2026negative

Bleichmar Fonti & Auld LLP said it is investigating Alignment Healthcare over allegations that the company and senior executives artificially inflated adjusted EBITDA to boost executive compensation. The firm cited a significant stock drop in announcing the investigation.

Why it matters — The investigation concerns allegations about ALHC’s financial reporting and executive compensation, matters relevant to investors monitoring the company.

ALHC Shareholder Notice: Alignment Healthcare Under Investigation for Potential Securities Fraud over Alleged Misrepresentations to Investors

PRNewsWire · 3 Nov 2026negative

Bleichmar Fonti & Auld LLP announced an investigation into Alignment Healthcare for potential securities fraud. The investigation concerns allegations that the company and senior executives artificially inflated adjusted EBITDA to boost executive compensation.

Why it matters — ALHC watchers may want to follow the investigation and the allegations involving the company’s financial reporting and executive compensation.

Alignment Healthcare Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Alignment Healthcare, Inc. - ALHC

PRNewsWire · 31 Oct 2026negative

Kahn Swick & Foti, LLC announced an investigation into the officers and directors of Alignment Healthcare, Inc., according to the PRNewswire headline. The excerpt identifies former Louisiana Attorney General Charles C. Foti, Jr., but provides no further details.

Why it matters — The investigation concerns the company’s officers and directors, making it relevant to investors monitoring ALHC’s corporate governance and legal matters.

Alignment Healthcare (NASDAQ: ALHC) Increasingly Scrutinized Over H3815 Cut Points And CMS Bonus Eligibility - HBSS

PRNewsWire · 30 Oct 2026negative

CMS lowered Alignment Healthcare’s California HMO contract H3815 from a 4.0 Star Rating to 3.5 for 2027. The excerpt says the contract serves 75% of the company’s health plan membership and that investors had raised concerns about its performance and CMS rating cut points.

Why it matters — H3815’s rating change affects a contract covering most of Alignment’s health plan membership and is drawing investor scrutiny.

FAQ

Frequently asked questions about ALHC stock

What is the ALHC stock price forecast for 2026-2027?

The 15 Wall Street analysts covering Alignment Healthcare, Inc. have a median 12-month price target of $10, with estimates ranging from $8 to $17. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALHC stock a buy right now?

Of the 15 analysts covering Alignment Healthcare, Inc., 9 rate it a Buy, 6 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alignment Healthcare, Inc. 42 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALHC?

As at 4 Nov 2026, Alignment Healthcare, Inc. ranks 42 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (77 of 100).

Will ALHC stock go up?

No one can know that. What the data says: the median 12-month target from 15 analysts implies +22.9% from the last close, and Ticker Nerd's factor model ranks Alignment Healthcare, Inc. 42 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALHC stock forecast for 2030?

No analyst covering Alignment Healthcare, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $17 over the next 12 months.

How has ALHC stock performed over the past year?

Alignment Healthcare, Inc. returned -52.4% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Alignment Healthcare, Inc. do?

Alignment Healthcare, Inc. is a managed healthcare company focused on Medicare Advantage plans for seniors in the United States.

What is the latest news on ALHC?

The most recent item we track (GlobeNewsWire, 4 Nov 2026): "ALHC Investigation Reminder: Alignment Healthcare Inflated EBITDA Triggers Securities Fraud Investigation for Investors – Contact BFA Law if You Lost Money". Bleichmar Fonti & Auld LLP said it is investigating Alignment Healthcare over allegations that the company and senior executives artificially inflated adjusted EBITDA to boost executive compensation. The firm cited a significant stock drop in announcing the investigation.

Company

About Alignment Healthcare, Inc.

Alignment Healthcare, Inc. is a managed healthcare company focused on Medicare Advantage plans for seniors in the United States. The company provides a consumer-centric healthcare platform designed to coordinate coverage and care through customized health plan offerings, local provider partnerships, and technology-enabled support. Its services are built to help members navigate benefits, access care, and manage their health through tools such as member portals, mobile apps, concierge-style assistance, and care coordination resources. Alignment Healthcare serves seniors and Medicare beneficiaries in selected U.S. markets, with a business model centered on improving the experience of health plan members while working closely with providers and care teams. Headquartered in Orange, California, Alignment Healthcare plays a specialized role in the managed care sector by combining insurance coverage with clinical and digital support services.

CEO Mr. John E. Kao · 1,849 employees · United States · https://www.alignmenthealth.com